All In Biotech

Drug Trial Radar · NCT00855920

Study Utilizing Rilonacept in Gout Exacerbations

A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare

Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Mar 2009

Primary completion

Feb 2010

Study completion Feb 2010

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 5, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.

Conditions

  • Acute Gout Flare

Interventions

  • RilonaceptDrug

    Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).

  • IndomethacinDrug

    Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).

  • Placebo (for Indomethacin)Other

    Placebo (for Indomethacin) orally TID for 12 days.

  • Placebo (for Rilonacept)Other

    Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 HoursTime frame: Pre-dose on Day 1 (Baseline); post-dose at 4, 8, 12, 24, 48, 72 hours and then daily up to Day 13 or until gout flare ends

Locations

44 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Burbank, California

  • Site not named

    Whittier, California

  • Site not named

    Clearwater, Florida

  • Site not named

    DeBary, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Orange Park, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Oviedo, Florida

  • Site not named

    Boise, Idaho

  • Site not named

    Elizabethtown, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Wheaton, Maryland

  • Site not named

    Detroit, Michigan

  • Site not named

    Stevenville, Michigan

  • Site not named

    Billings, Montana

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Burlington, North Carolina

  • Site not named

    Cary, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Wilmington, North Carolina

  • Site not named

    Willoughby Hills, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Lake Oswego, Oregon

  • Site not named

    Portland, Oregon

  • Site not named

    Johnstown, Pennsylvania

  • Site not named

    Limerick, Pennsylvania

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Bristol, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Forth Worth, Texas

  • Site not named

    Houston, Texas

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.